Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 6.98NGL Fine Chem Ltd demonstrates a mixed financial performance. The company shows strong solvency and profitability, indicating a solid foundation. Growth metrics are generally positive, driven by revenue, EPS, asset, and net income growth. However, operating profit growth lags. The company's coverage ratios are robust, reflecting a good ability to meet its obligations. Liquidity is adequate, although cash and operating cash flow ratios are weak. Efficiency ratios present challenges, particularly in fixed asset and capital turnover. Financial metrics are average, with book value as a relative strength but dividends and capital expenditures need attention. Despite some weaknesses, NGL Fine Chem's strategic positioning in the Healthcare Services sector supports a positive outlook, contingent on addressing operational inefficiencies and sustaining growth momentum.
Health Score : 6.98NGL Fine Chem Ltd demonstrates a mixed financial performance. The company shows strong solvency and profitability, indicating a solid foundation. Growth metrics are generally positive, driven by revenue, EPS, asset, and net income growth. However, operating profit growth lags. The company's coverage ratios are robust, reflecting a good ability to meet its obligations. Liquidity is adequate, although cash and operating cash flow ratios are weak. Efficiency ratios present challenges, particularly in fixed asset and capital turnover. Financial metrics are average, with book value as a relative strength but dividends and capital expenditures need attention. Despite some weaknesses, NGL Fine Chem's strategic positioning in the Healthcare Services sector supports a positive outlook, contingent on addressing operational inefficiencies and sustaining growth momentum.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
39.44
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
34.11
P/B RATIO
4.99
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
3.02
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
-10.09
EV/EBITDA RATIO
18.00
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹2657.6 as on Sep 1, 2026.
Growth Score : 8.80The company demonstrates strong growth in revenue, EPS, assets, and net income, indicating a positive trajectory. However, the decline in operating profit growth is a concern. The company's ability to sustain overall growth depends on improving operational efficiency and profitability.
Revenue Growth RateExcellentOperating Profit Growth RatePoorEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 23.26 | -12.58 | 21.94 | 8.55 | 36.14 |
| Operating Profit Growth Rate | -15 | -48.53 | 54.29 | -35.19 | 108.57 |
| Earnings Per Share (EPS) Growth | -12.02 | -58.92 | 101.57 | -48.88 | 127.87 |
| Asset Growth Rate | 33.82 | 3.61 | 24.04 | 21.63 | 26.1 |
| Net Income Growth Rate | -12.28 | -60 | 105 | -48.78 | 128.57 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Accent Microcell Ltd | 7.96 | 24.25 | Neutral | 57.00 | 18.28 | 44.00 |
| 2 | Lincoln Pharmaceuticals Ltd | 7.31 | 13.89 | Neutral | 98.00 | 43.88 | 88.00 |
| 3 | Kilitch Drugs (India) Ltd | 7.12 | 22.83 | Neutral | 37.00 | 9.27 | 30.00 |
| 4 | NGL Fine Chem Ltd | 6.98 | 34.11 | Neutral | 73.00 | 67.39 | 48.00 |
| 5 | Sakar Healthcare Ltd | 6.89 | 70.49 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 6 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 7 | Kopran Ltd | 6.60 | 40.82 | Undervalued | 62.00 | 6.30 | 26.00 |
| 8 | SMS Lifesciences India Ltd | 6.59 | 22.25 | Undervalued | 45.00 | 58.80 | 19.00 |
| 9 | Infinium Pharmachem Ltd | 6.42 | 33.97 | Neutral | 22.00 | 6.43 | 14.00 |
| 10 | Medicamen Biotech Ltd | 5.73 | 37.61 | Neutral | 20.00 | 6.94 | 10.00 |
| 11 | Albert David Ltd | 5.63 | -333.98 | Neutral | 5.00 | -2.62 | -1.00 |
| 12 | Zim Laboratories Ltd | 5.41 | 108.20 | Neutral | 30.00 | 1.11 | 6.00 |
| 13 | Remus Pharmaceuticals Ltd | 5.31 | 27.61 | Neutral | 57.00 | 20.97 | 46.00 |
| 14 | Ind-Swift Laboratories Ltd | 4.95 | 77.18 | Neutral | 45.00 | 4.89 | 41.00 |
| 15 | Venus Remedies Ltd | 4.83 | 23.37 | Neutral | 147.00 | 74.30 | 103.00 |
| 16 | Wanbury Ltd | 4.65 | 27.30 | Neutral | 88.00 | 15.98 | 43.00 |
| 17 | Nectar Lifescience Ltd | 3.83 | -0.80 | Neutral | -59.00 | -2.95 | -293.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
Quarterly Report⬤3rd Feb 26
Quarterly Financial Results Q3 FY 2025-26
BULLISH SENTIMENT
Concall Report⬤18th Nov 25
Q2 and H1 FY26 Earnings Conference Call
NEUTRAL SENTIMENT
NGL Fine Chem Ltd. is an Indian pharmaceutical company specializing in the manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. Its primary focus is on veterinary bulk drugs, complemented by a growing presence in human APIs. The company serves both domestic and international markets, emphasizing quality and regulatory compliance.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. NGL Fine Chem Ltd's P/E ratio (TTM) is 39.44, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. NGL Fine Chem Ltd's P/B ratio is 4.99, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. NGL Fine Chem Ltd's P/S ratio is 3.02, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. NGL Fine Chem Ltd's PEG ratio is -10.09.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. NGL Fine Chem Ltd's EV/EBITDA ratio is 18.00.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. NGL Fine Chem Ltd's ROE is 14.59%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. NGL Fine Chem Ltd's ROA is 13.37%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. NGL Fine Chem Ltd's ROCE is 17%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. NGL Fine Chem Ltd's operating margin is 14.57%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. NGL Fine Chem Ltd's net margin is 9.58%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. NGL Fine Chem Ltd's current ratio is 1.54.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. NGL Fine Chem Ltd's debt-to-equity ratio is 0.18.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. NGL Fine Chem Ltd's interest coverage ratio is 16.75.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. NGL Fine Chem Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. NGL Fine Chem Ltd's EPS is 127.87.
(Source line: "Ratios as of 26 Sept 2026, based on last traded price of ₹2657.60. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1990
Headquarters: Mumbai, Maharashtra
Core Offerings: Veterinary APIs, Pharmaceutical Intermediates, Human APIs, Contract Manufacturing
Stock Listing: NSE (NGLFINE), BSE (524774)
Promoter: K. G. Prabhu & Family / Prabhu Group
1990: Incorporated as NGL Fine-Chem Ltd. 1994: Commenced commercial production of veterinary bulk drugs. Over the years, the company expanded its manufacturing capabilities and product portfolio, focusing on quality and regulatory compliance, particularly in animal health. Present Day: Established as a specialized manufacturer of veterinary APIs and intermediates with a growing presence in human APIs and international markets.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Veterinary & Human APIs and Intermediates | Majority | N/A (Segment-wise EBITDA not reported) |
Veterinary APIs & Intermediates: Manufactures a wide range of active pharmaceutical ingredients primarily for animal health applications, catering to various therapeutic categories for livestock and pets.
Human APIs: Engaged in the development and manufacturing of a limited range of active pharmaceutical ingredients for human health, serving as an additional growth avenue.
Manufacturing Facilities: Operates state-of-the-art manufacturing facilities located in Tarapur, Maharashtra, with certifications to meet stringent global regulatory standards for quality and compliance.
Mr. Kalyan G. Prabhu - Chairman & Managing Director: A seasoned professional with extensive experience in the pharmaceutical industry, particularly in manufacturing and operations. He has been instrumental in the company's growth and strategic direction since its inception.
No major subsidiaries reported.
Bonus Issue: 1:1 in August 2021. Stock Split: 1:5 in February 2022 (Face value from ₹10 to ₹2). No major recent M&A or rights issues.
The NGL Fine Chem Ltd share price today is ₹2657.60 on NSE (NGLFINE), as of 26 Sept 2026.
As of 26 Sept 2026, NGL Fine Chem Ltd share price is ₹2657.60, with previous close ₹2657.60. Today's range is ₹2657.60 to ₹2657.60. The 52-week range is ₹N/A to ₹N/A.
As of today, NGL Fine Chem Ltd's market cap is ₹1,514.83 crore (Small Cap).
NGL Fine Chem Ltd's current P/E ratio is 39.44, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 32.50.
NGL Fine Chem Ltd's current P/B ratio is 4.99.
NGL Fine Chem Ltd's current dividend yield is N/A. Last dividend of ₹1.00 per share was declared on 14-Sep-2023.
NGL Fine Chem Ltd's EPS (TTM) is ₹127.87.
NGL Fine Chem Ltd. is an Indian pharmaceutical company specializing in the manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. Its primary focus is on veterinary bulk drugs, complemented by a growing presence in human APIs. The company serves both domestic and international markets, emphasizing quality and regulatory compliance.
NGL Fine Chem Ltd is promoted by K. G. Prabhu & Family / Prabhu Group, holding 72.74% as of 26 Sept 2026.
NGL Fine Chem Ltd is listed on NSE (NGLFINE) and BSE (524774). Its next quarterly results are expected on August 2024.
Book Value Per Share
